Stericycle Inc. (NASDAQ:SRCL) – Equities research analysts at Wedbush boosted their Q3 2016 earnings estimates for shares of Stericycle in a report issued on Thursday. Wedbush analyst A. Kaschalk now anticipates that the brokerage will earn $1.20 per share for the quarter, up from their previous estimate of $1.19. Wedbush has a “Neutral” rating and a $85.00 price target on the stock. Wedbush also issued estimates for Stericycle’s Q1 2017 earnings at $1.11 EPS, Q2 2017 earnings at $1.15 EPS, FY2017 earnings at $4.75 EPS, Q1 2018 earnings at $1.19 EPS and FY2018 earnings at $5.12 EPS.
Other research analysts also recently issued reports about the company. Jefferies Group reiterated a “buy” rating and set a $112.50 target price (down from $125.00) on shares of Stericycle in a research note on Wednesday, September 7th. Zacks Investment Research upgraded Stericycle from a “hold” rating to a “buy” rating and set a $117.00 price target for the company in a research note on Monday, July 11th. Wellington Shields downgraded Stericycle from an “accumulate” rating to a “hold” rating in a research note on Friday, July 29th. Macquarie started coverage on Stericycle in a research note on Thursday, August 25th. They issued a “neutral” rating and a $96.00 price target for the company. Finally, Northcoast Research downgraded Stericycle from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 20th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. Stericycle has a consensus rating of “Hold” and a consensus price target of $104.95.
Shares of Stericycle (NASDAQ:SRCL) opened at 80.26 on Monday. The stock has a 50 day moving average price of $83.43 and a 200-day moving average price of $101.33. Stericycle has a 52 week low of $76.76 and a 52 week high of $151.57. The firm has a market capitalization of $6.83 billion, a price-to-earnings ratio of 28.25 and a beta of 0.27.
Stericycle (NASDAQ:SRCL) last announced its earnings results on Thursday, July 28th. The company reported $1.18 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.18. Stericycle had a return on equity of 14.84% and a net margin of 7.22%. The company earned $891.60 million during the quarter, compared to analyst estimates of $910.29 million. During the same period last year, the company posted $1.14 earnings per share. The firm’s quarterly revenue was up 24.6% compared to the same quarter last year.
Institutional investors have recently bought and sold shares of the company. Jana Partners LLC purchased a new position in shares of Stericycle during the first quarter worth about $305,997,000. Generation Investment Management LLP purchased a new position in shares of Stericycle during the second quarter worth about $237,333,000. Baillie Gifford & Co. boosted its position in shares of Stericycle by 77.2% in the second quarter. Baillie Gifford & Co. now owns 2,940,515 shares of the company’s stock worth $306,166,000 after buying an additional 1,281,519 shares during the last quarter. Swedbank purchased a new position in shares of Stericycle during the second quarter worth about $104,155,000. Finally, USS Investment Management Ltd purchased a new position in shares of Stericycle during the first quarter worth about $80,866,000. 92.80% of the stock is owned by institutional investors.
In other news, EVP John P. Schetz sold 1,398 shares of the business’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $81.85, for a total transaction of $114,426.30. Following the completion of the transaction, the executive vice president now owns 1,088 shares of the company’s stock, valued at approximately $89,052.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Rodney F. Dammeyer sold 10,188 shares of the business’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $85.50, for a total value of $871,074.00. Following the transaction, the director now directly owns 10,188 shares of the company’s stock, valued at approximately $871,074. The disclosure for this sale can be found here. Insiders own 3.30% of the company’s stock.
Stericycle, Inc is a business-to-business services provider with a focus on regulated and compliance solutions for healthcare, retail and commercial businesses. The Company’s solutions include the collection and processing of specialized waste for disposal, the collection of personal and confidential information for secure destruction, and a range of training, consulting, recall/return, communication and compliance services.
Receive News & Ratings for Stericycle Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stericycle Inc. and related companies with MarketBeat.com's FREE daily email newsletter.